Nature Biotechnology

An artist's impression of Deep Visual Proteomics, a method based on a combination of imaging, deep learning and mass spectrometry

Single-cell-type tissue proteomics

Deep Visual Proteomics combines machine learning, automated image analysis and single-cell proteomics

Current issue

Increase vigilance against cyberattacks

Editorial 03 Aug 2022
HER3-addicted tumors: how biotechs are closing in

Elie Dolgin
News 09 Aug 2022
Verve takes base editors into humans

News in Brief 09 Aug 2022
Spatial charting of single-cell transcriptomes in tissues

Runmin Wei
Siyuan He
Nicholas E. Navin
Article 21 Mar 2022
Integrative spatial analysis of cell morphologies and transcriptional states with MUSE

Feng Bao
Yue Deng
Lani F. Wu
Article 28 Mar 2022
m⁶A RNA modifications are measured at single-base resolution across the mammalian transcriptome

Lulu Hu
Shun Liu
Chuan He
Article 14 Mar 2022

Contents

View all issues

Announcements

Nature Conference: RNA at the Bench and Bedside III

The third in a series of Nature Conferences highlighting the way RNA medicines continue to change the face of clinical practice. This conference explores progress in our understanding of the roles of RNAs in immune signaling and chronic disease associated with dysregulated inflammatory processes.
We are searching for a new Chief Editor

Nature Biotechnology currently has an open position for a visionary, dynamic Chief Editor, who will help further develop the journal as the leading publication in the field. The position will be based in one of our main offices in New York, London or Berlin.
We are seeking a Reviews Editor

Nature Biotechnology is seeking a highly motivated Associate or Senior Editor to join the team as our Reviews Editor.
We are seeking an Associate/Senior Editor

Nature Biotechnology is seeking a researcher to join our team as an Associate/Senior Editor. Candidates must have a PhD in an area relevant to immunology.

Nature Biotechnology is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Latest Research articles

High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects

Several engineered Cas13 variants achieve targeted RNA degradation with minimal collateral effects.

Huawei Tong
Jia Huang
Hui Yang
Article 11 Aug 2022
Bioengineered corneal tissue for minimally invasive vision restoration in advanced keratoconus in two clinical cohorts

A bioengineered cornea made of collagen restores vision in a pilot clinical study.

Mehrdad Rafat
Mahmoud Jabbarvand
Neil Lagali
Article Open Access 11 Aug 2022
Ras-mutant cancers are sensitive to small molecule inhibition of V-type ATPases in mice

Cancers with common KRAS mutations can be treated with an inhibitor of lysosomal acidification in mice.

Bhairavi Tolani
Anna Celli
Jonathan S. Weissman
Article Open Access 25 Jul 2022
Logic-gated antibody pairs that selectively act on cells co-expressing two antigens

Antibody pairs are made to act selectively on cells co-expressing two targets by engineering their Fc domains.

Simone C. Oostindie
Derek A. Rinaldi
Rob N. de Jong
Article Open Access 25 Jul 2022
Uncovering the mode of action of engineered T cells in patient cancer organoids

The dynamics and molecular mechanisms of T cell therapies are probed in cancer organoids.

Johanna F. Dekkers
Maria Alieva
Anne C. Rios
Article Open Access 25 Jul 2022
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants

Multiple variants of SARS-CoV-2 are inhibited by a trispecific DARPin.

Sylvia Rothenberger
Daniel L. Hurdiss
Jakob Trimpert
Article Open Access 21 Jul 2022

Latest Reviews & Analysis

- Engineered Cas13 variants with minimal collateral RNA targeting
  
  The application of CRISPR–Cas13 for targeted RNA degradation is hindered by the existence of collateral effects induced by Cas13. We screened hundreds of engineered Cas13 variants using a convenient and sensitive reporter system and obtained several variants with markedly reduced collateral activity and efficient on-target activity, suitable for in vivo applications.
  
  Research Briefing 12 Aug 2022
- Accessible bioengineered corneal tissue to address a blinding disease globally
  
  Porcine dermal collagen was chemically and photochemically bioengineered into an implantable tissue mimicking the human corneal extracellular matrix. The implant presents a simpler and safer method than donor cornea transplantation while delivering equivalent outcomes, and has restored vision to people with advanced keratoconus in resource-limited regions, where the burden of blindness is highest.
  
  Research Briefing 11 Aug 2022
- BEHAV3D: an imaging and transcriptomics platform that unravels T cell antitumor activity
  
  This study reveals a high level of behavioral heterogeneity in engineered T cells that target tumor organoids. Behavior-guided transcriptomics identified the gene signatures of T cells with highly potent serial cytotoxicity. Integration of the organoid and T cell transcriptomic data enabled the design of patient-specific combinatorial treatment to achieve an optimized response to cancer immunotherapies.
  
  Research Briefing 28 Jul 2022
- Precision cancer targeting with antibody pairs
  
  Logic-gated monoclonal antibodies have been designed to improve safety and efficacy.
  Robert T. Lawrence
  Peter D. Senter
  
  News & Views 25 Jul 2022
- A new route to vaccines using PROTACs
  
  An influenza vaccine is created by attenuating the live virus through targeted proteolysis.
  Brad Gilbertson
  Kanta Subbarao
  
  News & Views 22 Jul 2022
- Wastewater is a robust proxy for monitoring circulating SARS-CoV-2 variants
  
  Research Briefing 21 Jul 2022
- Framework for multiplicative scaling of single-cell proteomics
  
  Research Briefing 18 Jul 2022
- Identifying drug combinations that enhance treatment responses mediated by the tumor microenvironment
  
  Research Briefing 04 Jul 2022
- Profiling the total single-cell transciptome using droplet microfluidics
  
  Research Briefing 28 Jun 2022

News & Comment

Abalos Therapeutics---arenaviruses take on cancer

After >20 years of research at the intersection of virology and immunology, two brothers have launched a venture seeking to turn arenaviruses into an anticancer virotherapy.

Laura DeFrancesco
News Feature 12 Aug 2022
Forum: Bertozzi and Deshaies

Podcast 09 Aug 2022
CureVac sues BioNTech over mRNA technology

News in Brief 09 Aug 2022
A DNA Typewriter in living cells

Eleni Kotsiliti
Research Highlight 09 Aug 2022
Verve takes base editors into humans

News in Brief 09 Aug 2022
Epigenomics

Recent patents relating to epigenomic analyses, modification and engineering.

Patents 09 Aug 2022